Therapeutic agent in form of gel for treating herpetic infection manifestations in patients with burns and cold injuries

FIELD: medicine.

SUBSTANCE: therapeutic agent contains recombinant interferon specified in a group of: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, metronidazole, fluconazole and/or voriconazole, and a pharmaceutically acceptable base in the following proportions, g per 1 ml of the mixture: recombinant interferon, international units 100-10,000,000; metronidazole 0.00001-0.5; fluconazole and/or voriconazole 0.00001-0.5; pharmaceutically acceptable base - the rest. Besides, the therapeutic agent contains boric acid in an amount of 0.00001-0.5 g and hypromellose in an amount of 0.00001-0.5 g. As a pharmaceutically acceptable base, it contains macrogol 400 or macrogol 1500, or macrogol 4000.

EFFECT: higher efficacy of the compound.

2 cl, 5 ex

 

The drug is in the form of gel for the treatment of manifestations of herpetic infections in patients with burns and frostbite.

The invention relates to medicine, namely the creation of medicines in the form of gel for the treatment of manifestations of herpetic infections in patients with burns and frostbite, which has antiviral, immunomodulatory, anti-inflammatory, antifungal and antimicrobial action.

Currently, therapy gerpeticheskoi infection represents a significant challenge due to the chronic relapsing course of the disease, multifocal nature of the lesions, immunological shifts and anxiety-depressive disorders developing in the body of patients.

Significant challenges in the treatment of herpes occur in patients with burns and frostbites, particularly among socially disadvantaged patients. In this case, the source of the violation, including the reduction of protective forces of an organism, chronic fungal infection, exacerbated by HIV, developing due to the pathogenetic mechanisms of the effects of burns or frostbite, the development of mixed infection.

The objective of the invention is to develop tools for the treatment of herpes infections in patients with burns or frostbite.

Known treatment of patients with relapsing genital the NYM herpes in the formation of anxiety and depressive disorders, including specific antiviral therapy (RU 2270012 C2, A61K 31/522, 2006)

Known vaginal suppositories for the treatment of vaginal herpes containing recombinant interferon-alpha, metrogylum, fluconazole and boric acid (Obstetrics and gynecology, 2012, No. 3, S. 3).

However, this therapy for other patients. The authors of the invention not found in the available sources of information tools for the treatment of herpes in patients with burns or frostbite.

The technical result of the invention is effective treatment of herpes infections, including mixed infections in patients with burns or frostbite on the background developed immunodeficiency, including the socially disadvantaged patients, often with the original violations of protective forces of an organism, in the presence of chronic infection, including fungal infection.

To achieve the technical result the drug is in the form of gel for the treatment of widespread herpes infection in these patients, which has antiviral, immunomodulatory, anti-inflammatory, antifungal and antimicrobial action, contains recombinant interferon-alpha and interferon-beta or interferon-alpha and interferon-gamma, and contains metronidazole, fluconaz the l and voriconazole, boric acid and hypromellose in the following ratio of components, in grams per 1 ml of a mixture of:

recombinant interferon, ME100-10000000
metronidazolewithin 0.00001 to 0.5
fluconazole and voriconazolewithin 0.00001 to 0.5
boric acidwithin 0.00001 to 0.5
hypromellosewithin 0.00001 to 0.5
pharmaceutically acceptable baserest

As pharmaceutically acceptable basis proposed remedy contains macrogol 400, or macrogol 1500, or macrogol 4000.

The present invention is illustrated with specific examples of implementation, which, however, are not only possible, but clearly demonstrate the possibility of achieving the desired technical result.

Example 1. To obtain the claimed medicinal product is mixed with recombinant interferon-alpha and interferon-gamma, metronidazole, fluconazole and voriconazole, boric acid and macrogol 400 as pharmaceutically acceptable bases in the following ratio of components in g per 1 ml of the mixture:

Dose components chosen depending on the severity of the clinical situation, the prevalence of infection, the area of burns or frostbite, especially premorbid, concomitant infection.

Example 2. Carried out analogously to example 1. Except that they use instead of recombinant interferon-gamma interferon-beta, as well as pharmaceutically acceptable bases take macrogol 4000.

Example 3. Carried out analogously to example 1. Except that the mixture was added as a polymeric carrier macrogol 1500.

Example 4. Patient B., aged 47, of no fixed residence, was admitted to MBUS GKB №18, Ufa with a diagnosis of burn II IV-IV degree torso, the right lower limb 12% (9%), a fungal infection of the nails and feet. After the stabilization and normalization of hemodynamics on the second day was transferred to the treatment fluidizers installation of SAT-1. On day 7 at the beginning of septicaemia burn disease was noted a significant immunosuppression, which was characterized by fever leukocytosis and increased ESR.

On the background of standard treatment and bandaging the patient began to present complaints pronounced itching, burning, soreness in the areas of burns on the body and herpetic lesions on the glans penis. The bol is tion was observed anxiety-depressive disorders.

During the examination the patient had been found herpetic rash in the area of the perineum and the penis, as well as on the periphery of the burn wounds on the trunk. Lesions were multiple, grouped form, tend to merge small bubbles filled with liquid, with redness around them. Lesions on the genitals and around the burn wounds on the body were treated with the medication in the form of a gel of example 1.

Treatment of lesions produced twice a day for 5 days. After 2 days formed surface erosion with scanty serous discharge yellowish color. On the 4th day appeared crust, which later disappeared.

Then it was a landmark how agressively to debride and autodermoplasty split mesh flap. After complete epithelialization and holding of early rehabilitation the patient was discharged 40 days of treatment.

Example 5. Patient F., 23, enrolled in BUS GKB №18, Ufa with a diagnosis of General hypothermia I-II degree. Frostbite I-II, upper and lower extremities 6%. Received within 8 hours of injury. A history of drug use, private infectious disease. The Department conducted a warm-physical methods, infusion and antibiotic therapy. Normalization of body temperature occurred during the first day when ationale. On the third day there was a sharp rise of temperature to 39-40°C, weakness, itching and burning in the genital area and in the parts of frostbite. Emotionally depressed state.

Genital herpes is manifested in the form of lesions on the vulva, labia lips, anus, vagina, inner side of thighs and buttocks. Had pruritus and stinging during urination.

Treatment of widespread herpes manifestations produced by cultivation of the medicinal product in the form of a gel according to example 2.

During the first day of itchy rash was followed by the appearance of small bubbles of liquid and unclear content. On the second day bubbles opened, on the third day marked the beginning of the healing process, part of the RAS scarce and detachable cover, which when I stopped in over the next two to four days.

Resolution infectious viral process occurred in all sections completely in 5 days. 14 day improved the General condition, decrease in anxiety and fear.

Thus, developed a new therapeutic agent based on the available raw materials, with high therapeutic activity, exhibiting a complex effect on the common manifestations of herpetic process on the background of mixed infection in the body. You the early combination of active components in adverse situations, the development of herpetic infection to stop this process, to promote healing of lesions in General immunokorrigiruyuschy impact on the organism in patients with immunocompromised and severe course of the disease.

1. The drug is in the form of gel for the treatment of manifestations of herpetic infections in patients with burns or frostbite containing recombinant interferon-alpha and interferon-beta or interferon-alpha and interferon-gamma, metronidazole, fluconazole and voriconazole, boric acid and hypromellose in the following ratio of components, in grams per 1 ml of a mixture of:

recombinant interferon, ME100-10000000
metronidazolewithin 0.00001 to 0.5
fluconazole and voriconazolewithin 0.00001 to 0.5
boric acidwithin 0.00001 to 0.5
hypromellosewithin 0.00001 to 0.5
pharmaceutically acceptable baserest

2. Drug under item 1, characterized in that as a pharmaceutically acceptable bases contains macrogol 400, or macrogol 1500, or macrogol 4000.


 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula:

,

wherein: each D and Z is independently absent or represents an optionally substituted linear aliphatic group containing zero to eight carbons, wherein 'aliphatic' refers to an alkyl, alkenyl or alkynyl group, and 'optionally substituted' refers to substituting by replacing independently one, two or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO2, -N3, -CN, -NH2, -NH-C1-C12-alkyl, -NH-C2-C8-alkenyl, -NH-C2-C8-alkynyl, -NH-C3-C12-cycloalkyl, -dialkylamino, -O-C1-C12-alkyl, -NHC(O)-C1-C12-alkyl, -NHC(O)-C2-C8-alkenyl, -NHC(O)-C2-C8-alkynyl, -NHC(O)-C3-C12-cycloalkyl; each A and E is independently absent or represents a cyclic group with the above cyclic group is independently specified in a group consisting of aryl or heteroaryl, each of which is optionally substituted; 'aryl' refers to phenyl, naphthyl, tetrahydronaphthyl, indanyl or idenyl; 'heteroaryl' refers to pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl or quinoxalinyl; 'optionally substituted' refers to substituting by replacing independently one, two, three or more hydrogen atoms by substitutes specified by -F, -Cl, -Br, -I, -OH, -NO2, -N3, -CN, -NH2, -NH-C1-C12-alkyl, -NH-C2-C8-alkenyl, -NH-C2-C8-alkynyl, -NH-C3-C12-cycloalkyl, -dialkylamino, -O-C1-C12-alkyl, -NHC(O)-C1-C12-alkyl, -NHC(O)-C2-C8-alkenyl, -NHC(O)-C2-C8-alkynyl, -NHC(O)-C3-C12-cycloalkyl; T is absent or represents an optionally substituted aliphatic group containing 1 to 24 carbons; 'aliphatic' refers to an alkyl, alkenyl or alkynyl group; 'optionally substituted' refers to substituting substituting by replacing independently one, two, three or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO2, -N3, -CN, -NH2, -NH-C1-C12-alkyl, -NH-C2-C8-alkenyl, -NH-C2-C8-alkynyl, -NH-C3-C12-cycloalkyl, -dialkylamino, -O-C1-C12-alkyl, -NHC(O)-C1-C12-alkyl, -NHC(O)-C2-C8-alkenyl, -NHC(O)-C2-C8-alkynyl, -NHC(O)-C3-C12-cycloalkyl; one to four of A, D, E, T and Z are absent; the ring B is specified in imidazolyl, pyrazolyl, 1,3,4-thiazolyl, and 1,3,4-oxadiazolyl, and the ring B is bound to J through atom C and bound to Z, E, T, A and D through atom C; in each specific case, R1 is independently specified in a group consisting of hydrogen, halogen, cyano optionally substituted by C1-C4alkyl, -O-R11, -NRaRb, -C(O)R11, -CO2R11 and -C(O)NRaRb; in each specific case, R11 independently represents hydrogen or optionally substituted C1-C8alkyl; in each specific case, each Ra and Rb are independently specified in hydrogen, C1-C8alkyl and C2-C8alkenyl; u is independently equal to 1, 2 or 3; Q and J represent R6 is specified in a group consisting of -C(O)-R12, -C(O)-C(O)-R12, -S(O)2-R12, and -C(S)-R12; in each specific case, R12 is independently specified in a group consisting of -O-R11, -NRaRb, and -R13; and in each specific case, R13 is independently specified in a group consisting of: hydrogen, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C3-C8cycloalkyl and C3-C8cycloalkenyl, each of which is optionally substituted; 'optionally substituted' refers to substituting independently by replacing one, two, three or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO2, -N3, -CN, -NH2, -NH-C1-C12-alkyl, -NH-C2-C8-alkenyl, -NH-C2-C8-alkynyl, -NH-C3-C12-cycloalkyl, -dialkylamino, -O-C1-C12-alkyl, -NHC(O)-C1-C12-alkyl, -NHC(O)-C2-C8-alkenyl, -NHC(O)-C2-C8-alkynyl, -NHC(O)-C3-C12-cycloalkyl, which inhibit an RNA-containing virus, particularly hepatitis C virus (HCV).

EFFECT: preparing hepatitis C inhibitors.

38 cl, 22 tbl, 516 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula (I), which possess the properties of HCV polymerase inhibitors. In formula , is specified in a group consisting of a single carbon-carbon bond and a double carbon-carbon bond; R1 and R3 are specified in hydrogen and methyl; R2 represents hydrogen; R5 is specified in a group consisting of hydrogen, hydroxy, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxy, C2-C6alkenyloxy, C3-C6alkynyloxy and halo; L represents a bond, and R6 represents a condensed 2-ring carbocyclyl, wherein each substitute is optionally substituted by one or more substitutes independently specified in a group consisting of RE, RF, RG, RH, RI, RJ and RK; or L is specified in a group consisting of a bond, C≡C, C(O)N(RC), N(RD)C(O), C1-C2-alkylene, C(H)2O, OC(H)2, cyclopropyl-1,2-ene, C(H)2N(RL), N(RM)C(H)2, C(O)CH2 and CH2C(O), and R6 is specified in a group consisting of C5-C6-carbocyclyk and 5-6-merous heterocyclyl, wherein each substitute is optionally substituted by one or more substitutes independently specified in a group consisting of RE, RF, RG, RH, RI, RJ, RK, RL and RM; the R4, RE, RF, RG, RH, RI, RJ, RK, RL and RM values are presented in the patent claim.

EFFECT: invention refers to a pharmaceutical composition containing the above compounds, to using the compounds for producing a drug preparation for HCV RNA polymerase inhibition and hepatitis C treatment, and to a method for preparing the above compounds.

21 cl, 46 dwg, 42 tbl, 140 ex

FIELD: medicine.

SUBSTANCE: invention refers to a medicated product based on a chemical compound of 7-[N'-(4-trifluoromethylbenzoyl)-hydrazinocarbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid (NIOH-14, N.N. Vorozhtsov Novosibirsk Institute Of Organic Chemistry) in a dose of 4 to 60 mg/kg of body weight, possessing the anti-smallpox virus activity, as well as a method for producing and using for the smallpox virus for preventing and treating mammals involving oral administration once a day in a dose range from 4 to 60 mg/kg of the mammalian body weight. A method for producing the medicated product possessing the anti-smallpox virus activity involves diluting and performing a reaction of 4-trifluorobenzoic acid hydrazide and 3,3a,4,4a,5,5a,6.6a-octahydro-1,3-dioxo-4,6-etheno-cycloprop[f]-furane in a molar ratio of 1:1 in a solvent and mixing the produced suspension until producing sediments which are removed from the solution, filtered and dried to produce an end product that is a chemical compound of 7-[N'-(4-trifluoromethylbenzoyl)-hydrazinocarbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid (NIOH-14, N.N. Vorozhtsov Novosibirsk Institute Of Organic Chemistry). The solvent is ethyl or isopropyl alcohol; preparing the suspensions, separating and filtering the sediments are performed at a temperature of +2-10°C, while a dry product yield makes 96.0%.

EFFECT: invention provides the less toxic preparation of the medicated product, possessing the high anti-smallpox virus activity.

4 cl, 4 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention provides an agent for arresting undesirable vaccinal reactions and complications during primary vaccination with variolar vaccines, characterised by that it contains 7-[N'-(4-trifluoromethylbenzoyl)-hydrazine-carbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid, and a method of using said agent in doses of 3.3-50 mg/kg body mass once a day on the day of vaccination and two days after vaccination, which does not reduce potency of the vaccine.

EFFECT: arrests undesirable vaccinal reactions and complications during primary vaccination with variolar vaccines.

2 cl, 5 ex, 4 tbl

Antiviral agent // 2542488

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to an antiviral agent and aims at inactivating a wide range of viruses. The antiviral agent contains an active agent presented by particles of at least one type of iodide formed by iodine and an element formed in 4-6th periods of the 8-10th or 12-15th groups of the periodic table, Cu or Au. The above element found in the 4-6th periods of the 8-10th or 12-15th groups of the periodic table represents Sb, Ir, Ge, Sn, Tl, Pt, Pd, Bi, Fe, Co, Ni, Zn, In or Hg. What is also presented is the antiviral agent containing particles of at least one type of a cuprous compound as an active ingredient. The above cuprous compound represents chloride, acetate, sulphide, iodide, bromide, peroxide, oxide or thiocyanide.

EFFECT: using the group of inventions provides the agent having the high antiviral activity; the above agent is able to exhibit and maintain its antiviral activity easily since it requires no preparation or special washing.

5 cl, 4 tbl, 27 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula I, their pharmaceutically acceptable salts and crystalline forms, which possess the properties of HCV polymerase inhibitor. In formula I is specified in a group consisting of a single carbon-carbon bond and a double carbon-carbon bond; R1 represents hydrogen; R2 is specified in a group consisting of hydrogen and halo; R3 represents hydrogen; R4 is specified in a group consisting of halo, C1-C6alkyl, C1-C6alkylsulphonyl and 5-6-merous heteroaryl containing heteroatom specified in N, O and S, wherein alkyl is optionally substituted by one or more hydroxy; R5 is specified in a group consisting of hygrogen, hydroxy, C1-C6alkyloxy and halo; L is specified in a group consisting of C(RA)=C(RB), ethylene and cyclopropyl-1,2-ene; RA and RB are independently specified in a group consisting of hydrogen, C1-C6alkyl, C1-C6alkyloxy and halo; R6 represents C6aryl optionally substituted by one or more substitutes independently specified in a group consisting of RE, RF, RG, RH, RI and RJ; the substitutes RE, RF, RG, RH, RI and RJ are presented in the patent claim.

EFFECT: invention refers to the pharmaceutical composition containing the above compounds, to using the compounds for inhibiting HCV RNA-polymerase and treating hepatitis C and to a method of preparing the above compounds.

40 cl, 23 dwg, 7 tbl, 40 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: presented inventions refer to a lyophilised composition for inducing an immune response to flavivirus, compositions for preparing the above lyophilised composition, and a method for preparing the lyophilised composition. The characterised lyophilised composition contains an effective amount of live attenuated flavivirus, one or more stabilising agents, one or more buffer components, lactose and amorphous mannitol, which is prepared by lyophilising mixture containing an effective amount of live attenuated flavivirus, one or more stabilising agents, one or more buffer components, lactose and mannitol; flavivirus can be chimeric flavivirus. Preparing the above lyophilised composition involves freezing the components and drying them thereafter.

EFFECT: inventions enable preparing the transportation and storage stable compositions containing flavivirus.

31 cl, 13 dwg, 10 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gastroenterology, and can be applied as a method of treating hormone-dependent/hormone-resistant ulcerative colitis complicated by opportunistic infections. That is ensured by measuring herpes simplex virus type 1 IgG, herpes virus type 6 IgG, cytomegalovirus IgG, mycoplasm IgG, Chlamydia IgG. If herpes simplex virus type 1 IgG is 185 units/ml and more, and IgM is 0.4 units/ml and more, herpes virus type 6 IgG is 1.5 units/ml and more, cytomegalovirus IgG k is 185 units/ml and more, IgM is 3.4 units/ml and more, mycoplasm IgG is 119 units/ml and more, IgM is 0.4 units/ml and more, Chlamydia IgG is 105 units/ml and more, IgM is 0.8 units/ml and more, a systemic transplantation of allogenic mesenchymal stem cells in a dose of 150-250 million cells.

EFFECT: using the given method enables providing the more effective therapeutic treatment of hormone-dependent/hormone-resistant ulcerative colitis, promotes CMV elimination with no anti-viral therapy required and overcoming of hormone-dependency/hormone-resistance.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pyrimidine derivatives of structural formula (I-L0) and their crystalline forms possessing the inhibitory activity on the hepatitis C virus (HCV) polymerase. In formula is specified in a single or double carbon-carbon bond; R1, R2 and R3 represent hydrogen; R4 is specified in halo, C1-C6alkyl, C2-C6alkinyl, amino, C1-C6alkylsulphonyl, C3-C10carbocyclyl and 5-6-merous heterocyclyl having a heteroatom specified in a group consisting of O and S, wherein amino is optionally substituted by one or two C1-C6alkylsulphonyls, and C1-C6alkyl and C2-C6alkynyl are optionally substituted by one or more substitutes optionally specified in a group consisting of halo, oxo, hydroxy, C1-C6alkyloxy and trimethylsilyl, and C3-C10carbocyclyl and 5-6-merous heterocyclyl are optionally substituted by substitutes specified in C1-C6alkyl, halo and amino, wherein amino is optionally substituted by one or two C1-C6alkylsulphonyls; R5 is specified in a group consisting of hydrogen, hydroxy, C1-C6alkyloxy and halo; R6 represents a condensed 2-ring C3-C10carbocyclyl optionally substituted by substitutes specified in RE, RF, RG, RH, RI, RJ and RK, the values of which are specified in the patent claim.

EFFECT: invention refers to a pharmaceutical composition containing the above compounds, to using the compounds for producing a therapeutic agent for hepatitis C, to an intermediate compound for producing the compound of structural formula (I-L0) and to a method for preparing the above compounds and their crystalline forms.

70 cl, 23 dwg, 9 tbl, 83 ex

FIELD: veterinary medicine.

SUBSTANCE: cultivation of a culture of continuous BHK cells is carried out for 48-72 hours to the concentration of (2.5-3.0)×106 cells/ml, followed by infecting the cells with rabies virus at a dose of 0.01-0.1 MMLD50/cells. It is maintained at a temperature of 38.5-39.5°C for 60-90 minutes, followed by dilution with growth medium to the concentration of the cell subline of (0.5-0.6)×106 cells/ml and continuation of culturing the resulting suspension for 48-72 hours at a temperature of 37-38°C and pH 7.1-7.3. After which the virus-containing suspension is cooled to a temperature of 4-8°C at pH 7.8-8.0 and tris (hydroxymethyl)aminomethane and disodium salt of ethylenediaminetetraacetic acid is added, taken in the final concentrations of 0.7-0.9% and 0.006-0.01%, respectively. To inactivate the virus, β-propiolactone is applied in the bioreactor.

EFFECT: use of this method enables to improve the quality of the desired product by increasing the yield of viral antigen, the accumulation of virus particles, glycoprotein which is responsible for production of virus-neutralising antibodies, and enables to improve stabilisation of the antigenic properties of the viral glycoprotein.

4 cl, 1 tbl, 9 ex

FIELD: biotechnology.

SUBSTANCE: strain Trametes versicolor is proposed, used for production of antifungal agents against fungi of the genus Penicillium. The strain is deposited in the RCIM under the number F-1024.

EFFECT: strain has high chitinase and fungicidal activity.

4 dwg, 1 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: method of producing a carbon sorbent with antibacterial and antimycotic properties includes impregnating granules of a carbon hemosorbent with 10-50% aqueous solution of glycolic acid for 7-9 hours at room temperature. The ratio of the hemosorbent to the modifier solution of glycolic acid is 1:1. Further, drying is carried out for an hour at 100-110°C. Polycondensation of glycolic acid on the carbon hemosorbent is carried out in two steps: at 185-205°C for 1 hour, at 215-235°C for not less than 5 hours, on a sand bath. The disclosed modified carbon sorbent with antibacterial and antimycotic properties is granules with a round shape, contains not less than 5% polyglycolide, characterised by a specific adsorption surface area of less than 250 m2/g and total pore volume of less than 0.50 cm3/g.

EFFECT: improved properties of the sorbent.

2 cl, 2 tbl, 2 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to antifungal compounds based on 3,5,8-trioxabicyclo[5,1,0]octane derivatives, obtained by trans-opening of its epoxide cycle, namely 6-(arylthio)-1,3-dioxepan-5-ols in racemic and enantiopure form of the general formula Ia and Ib , where at R1=F, R2=H, R3=H; at R1=Br, R2=H, R3=H; at R1=H, R2=Br, R3=H; at R1=H, R2=H, R3=Br.

EFFECT: compounds of formula Ia and Ib possess low toxicity and high antifungal activity with respect to fungi Candida albicans, Aspergillus fumigatus, Epidermophyton floccosum, Mucor pusilos, Saccharomyces cerevisiae and can be applied in medicine and veterinary.

2 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: as an active substance, the composition contains butoconazol, a base that is a combination of a hydrophobic ingredient, a hydrophilic ingredient and an emulsifier, and also a gel-forming polymer. Hydroxypropylstarch phosphate is preferentially used as the gel-forming polymer. A method for preparing the declared composition consists in the fact that a mixture of butoconazol with a portion of the hydrophilic ingredient, the hydrophobic ingredient and emulsifier is added with a dispersion of the gel-forming polymer in the rest of the hydrophilic ingredient; the produced mixture is agitated homogenously with a preserving agent added where it might be necessary.

EFFECT: new pharmaceutical composition is characterised by a high level of antifungal activity, stability both at a storage temperature, and at a use temperature, and good pack extrusion.

14 cl, 2 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention represents an antifungal preparation in suppositories for children containing recombinant human interferon 2α and fluconazole, wherein lysozyme, Licopid and dimephosphone are additionally introduced.

EFFECT: preparation possesses the high clinical effectiveness in the fungal diseases in children that leads to reducing the length of treatment and prolonging the intercurrent period.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to the field of medicine, namely to pharmacology, and describes a composition, containing fulvic acid or its salt and an antifungal compound, selected from fluconazole and amphotericin B. In accordance with the first version of the implementation the composition contains about 10 ml/kg of a solution of from about 0.25% to about 1% (wt/vol) fulvic acid or its salt and of about 10 mg/kg fluconazole. In accordance with the second version of the implementation the composition contains 0.25% (wt/vol) of the solution of fulvic acid or its salt and from about 0.06 mg/l to about 0.5 mg/l of amphotericin B.

EFFECT: invention can be used in a method of treating a fungal infection of the human or animal body, the method includes the introduction to an object, requiring it, of a therapeutically effective quantity of the composition.

11 cl, 1 dwg, 10 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions refers to veterinary science and is applicable for treating the animals suffering from bacteriosis and yeast mycosis. A declared preparation contains oxytetracycline hydrochloride, sulphadimine, ampicillin sodium, nistatine, a solvent and the active substance conduit dimethyl sulphoxide, the quick-relief anaesthetic lidocaine in the following proportions, wt %: ampicillin sodium 4.0-8.0, oxytetracycline hydrochloride 2.0-4.0, nistatine 1.0-2.0, sulphadimine 2.0-4.0, novocaine 0.25-0.5, lidocaine 0.25-0.5, dimethyl sulphoxide 10.0-20.0, 1,2-propylene glycol - the rest. A method of treating the animals consists in administering the declared preparation in a dose of 0.1-0.2 cm3 per 1 kg of body weight.

EFFECT: using the declared group of inventions is high-efficiency for treating the animals suffering from bacteriosis and yeast mycosis and enables improving livestock farms with an unfavourable incidence of bacteriosis and yeast mycosis.

5 cl, 9 ex

FIELD: chemistry.

SUBSTANCE: preparation can be applied for elimination of fungi and in treatment of diseases, caused by fungi, as well as for the prevention of damage by fungi to different materials and agricultural products. The fungicidal preparation represents an associate of 5-[3,5-dichloro-2-hydroxybenzylidine)amino]-4-hydroxy-1H-pyrimidine-2-one with 1,2,3,4,5-pentahydroxy-6-methylaminohexane and corresponds to the following formula: . Compounds were obtained in the crystalline form, and their structure is proved by spectra of proton magnetic resonance in dimethylsulphoxide.

EFFECT: preparation has a wide spectrum of action and high solubility, which increases efficiency of its application in the form of solutions.

2 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to compositions and polymeric materials for biomedical use, comprising silver nanoparticles (0.0005-0.02 wt %) stabilised by amphiphilic copolymers of maleic acid (0.0008-0.05 wt %), low molecular weight organic amines (0.0002-0.04 wt %) and water. In addition, the said composition may additionally comprise the polymeric structure-forming agent.

EFFECT: introduction to the composition of the polymer structure-forming agent enables to obtain the macroporous structured hydrogel materials having prolonged bactericidal and antifungal action.

3 cl, 2 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to a composition containing encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters, or triterpene alcohol - betulin, which may be used in medicine for treating and preventing viral infections caused by DNA and RNA-containing viruses, such as influenza viruses, oncogenic viruses, herpes virus, herpes zoster virus, as well as infections caused by gram-positive and gram-negative bacteria: Staphylococcus spp., Streptococcus spp., Enterococcus spp., Shigella spp., Escherichia spp., Salmonella spp., Proteus spp., Acinetobacter spp., Citrobacter spp., Pseudomonas spp., Serratia spp., Klebsiella spp., Antracoides spp., Cryptococcus spp., pathogenic fungi of the genus Microsporum, Trichophyton, Nocardia, Aspergillus, yeast-like fungi of the genus Candida, including multiresistant strains, as well as Actinomycetes and some pathogenic protozoa: Entamoeba histolytica, Trichomonas vaginalis. The invention presents the composition containing an active ingredient presented by 0.5 wt % of betulin or 0.5 wt % of encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters and others, and carriers presented by: β-cyclodextrins, fullerene, lecithins and polymers binding to the ingredients to form ingredient-carrier complexes, and excipients.

EFFECT: higher efficacy of using the composition.

3 cl

FIELD: chemistry.

SUBSTANCE: invention refers to preparing (5Z,9Z)-5,9-docosadienoic acid of formula (1) exhibiting the inhibitory action on human topoisomerase I. (5Z,9Z)-5,9-Docosadienoic acid is prospective as a drug preparation possessing antitumour, antiviral and antibacterial action. Substance of the method consists in the fact that tetrahydropyrane ester of 5,6-heptadien-1-ole (4) and 1,2-pentadecadiene (5) interacts with Grignard reagent RMgX (R = Me, Et, Pr, Bu, Oct; X = Cl, Br, I) in diethyl ester in the presence of metal Mg (powder) and catalyst titanocendichloride Cp2TiCl2, in molar ratio (4):(5) : RMgX : Mg : Cp2TiCl2=10:12:(30-50):32:(0.4-0.6), in the argon atmosphere at temperature 0-35°C at atmospheric pressure over 6-10 h; the reaction mixture is processed with 5% aqueous HCl to prepare 2-[(5Z,9Z)-5,9-docosadien-l-yloxy]tetrahydro-2H-pyrane (6), which is oxidised by Jones reagent.

EFFECT: improving the properties.

2 cl, 1 dwg, 1 tbl, 15 ex

Up!